Protara Therapeutics, Inc. (TARA)

Protara Therapeutics' stock has been impacted by clinical data presentations, financial results announcements, regulatory milestones, a public offering, and participation in investor conferences. Interim results from the ADVANCED-2 trial showed a 68% complete response rate at six months in BCG-unresponsive bladder cancer patients. TARA-002 received Fast Track and Breakthrough Therapy designations from the FDA for treating pediatric patients with macrocystic and mixed cystic lymphatic malformations. The company completed an oversubscribed $86 million public offering. Over the past 52 weeks, TARA stock has traded between $2.77 and $7.82, with a share price of $5.45 as of May 4, 2026.

There is no explicit information indicating demand seasonality for Protara Therapeutics' products and services. Demand is primarily driven by clinical trial progress, regulatory approvals, and the prevalence of the diseases they aim to treat.

Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer and rare diseases. Their portfolio includes TARA-002, a cell-based therapy for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement therapy for patients on parenteral nutrition.

Protara Therapeutics is headquartered in New York, USA. TARA-002 is being developed for the U.S. market, and its foundational component, OK-432, is marketed in Japan and Taiwan. The company's direct operational geographic footprint beyond its U.S. headquarters is not extensively detailed.

Protara Therapeutics' brand reputation has been positively influenced by positive clinical trial results for TARA-002, FDA designations for lymphatic malformations, and a consensus rating of "Moderate Buy" from analysts. No specific negative events affecting the company's reputation were found.

Protara Therapeutics has 116 institutional owners and shareholders holding a total of 40,829,573 shares. Major institutional owners include Janus Henderson Group Plc, Velan Capital Investment Management LP, BlackRock, Inc., Vanguard Group Inc, Blackstone Group Inc, Acorn Capital Advisors, Llc, Sio Capital Management, LLC, AIGH Capital Management LLC, Catalio Capital Management, LP, and Integral Health Asset Management, LLC.